KNRS

Extraordinary General Meeting of Kinarus Holding approved all resolutions relating to the envisaged Business Combination with Curatis

Retrieved on: 
Wednesday, March 13, 2024
Medicine, Drug development, SIX Swiss Exchange, Transaction, Business analyst, KNRS

Basel, Switzerland, 1 March 2024: Kinarus Therapeutics Holding AG (SIX:KNRS) (“Kinarus Holding”, “KNRS” or the “Company”), a SIX Swiss Exchange listed therapeutic drug development company announced today that at the Extraordinary General Meeting of Kinarus Holding held on Friday, 1 March 2024, the shareholders of Kinarus Holding have approved with sweeping majorities all resolutions relating to the envisaged Business Combination with Curatis AG, a Basel-Landschaft incorporated medicine distribution and drug development company predominantly focused on orphan/ultra-orphan diseases and specialty care diseases (“Curatis”).

Key Points: 
  • Basel, Switzerland, 1 March 2024: Kinarus Therapeutics Holding AG (SIX:KNRS) (“Kinarus Holding”, “KNRS” or the “Company”), a SIX Swiss Exchange listed therapeutic drug development company announced today that at the Extraordinary General Meeting of Kinarus Holding held on Friday, 1 March 2024, the shareholders of Kinarus Holding have approved with sweeping majorities all resolutions relating to the envisaged Business Combination with Curatis AG, a Basel-Landschaft incorporated medicine distribution and drug development company predominantly focused on orphan/ultra-orphan diseases and specialty care diseases (“Curatis”).
  • Closing of the Transaction is expected to occur at the end of April 2024.
  • In addition to Kinarus Holding shareholder approval, completion of the proposed Business Combination is subject to satisfaction of certain other conditions.

Kinarus Therapeutics Announces Personnel Changes

Retrieved on: 
Wednesday, July 12, 2023
Drug development, Probability, Therapy, Hangzhou, SIX Swiss Exchange, Exchange, Financial audit, KNRS, Patent, CFO, Knowledge, API, IPF, Pioglitazone, Humanitarian use licenses, MAP, Pharmaceutical industry, Muthiri kinaru

Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.

Key Points: 
  • Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.
  • Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “We would like to thank Subhasis for his invaluable support of Kinarus while we navigated the company through these turbulent markets.
  • His considerable experience contributed to Kinarus’ ability to list on the Swiss Exchange last year via our fully completed reverse takeover transaction.
  • Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland.

Kinarus Therapeutics Announces Personnel Change

Retrieved on: 
Wednesday, July 12, 2023
Drug development, Probability, Therapy, Hangzhou, SIX Swiss Exchange, Exchange, Financial audit, KNRS, Patent, CFO, Knowledge, API, IPF, Pioglitazone, Humanitarian use licenses, MAP, Pharmaceutical industry, Muthiri kinaru

Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.

Key Points: 
  • Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, announced that its interim-CFO, Mr Subhasis Roy, who worked as a consultant for the company, is leaving to pursue other opportunities.
  • Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “We would like to thank Subhasis for his invaluable support of Kinarus while we navigated the company through these turbulent markets.
  • His considerable experience contributed to Kinarus’ ability to list on the Swiss Exchange last year via our fully completed reverse takeover transaction.
  • Kinarus Therapeutics Holding AG (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland.

Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting

Retrieved on: 
Thursday, June 29, 2023
Drug development, Probability, Therapy, Bank statement, Compensation, Execution management system, Harikumar, Radisson Blu Hotel Hamburg, AGM, KNRS, Labor Management Reporting and Disclosure Act of 1959, Annual report, Management, Senior, Knowledge, Pioglitazone, Professional Football Compensation Committee, CHF, Proxy, Banking license, Compensated emancipation, Annual general meeting, Audit, Muthiri kinaru

Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.

Key Points: 
  • Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.
  • Furthermore, the shareholders granted discharge to the members of the Board of Directors and Executive Management for the financial year 2022.
  • The “Invitation to the 2023 Annual General Meeting” with full proposals and explanations on the agenda items are available on Kinarus’ website at https://ir.kinarus.com/2023-agm/.
  • Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.

Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting

Retrieved on: 
Thursday, June 29, 2023
Drug development, Probability, Therapy, Bank statement, Compensation, Execution management system, Harikumar, Radisson Blu Hotel Hamburg, AGM, KNRS, Labor Management Reporting and Disclosure Act of 1959, Annual report, Management, Senior, Knowledge, Pioglitazone, Professional Football Compensation Committee, CHF, Proxy, Banking license, Compensated emancipation, Annual general meeting, Audit, Muthiri kinaru

Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.

Key Points: 
  • Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting ("AGM"), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.
  • Furthermore, the shareholders granted discharge to the members of the Board of Directors and Executive Management for the financial year 2022.
  • The “Invitation to the 2023 Annual General Meeting” with full proposals and explanations on the agenda items are available on Kinarus’ website at https://ir.kinarus.com/2023-agm/.
  • Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.

Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity

Retrieved on: 
Tuesday, June 27, 2023
Knowledge, Drug development, Probability, Pioglitazone, Therapy, Humanitarian use licenses, Hangzhou, KNRS, Muthiri kinaru

Basel, Switzerland, June 26, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of subordinated bridge loan agreements with existing shareholders to ensure further liquidity is available to Kinarus during the period of time required for bridging the pending transfer of funds pursuant to a CHF1.5 million convertible loan investment from ChaoDian (Hangzhou) Investment Management Co (CDIM), in Kinarus.

Key Points: 
  • Basel, Switzerland, June 26, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of subordinated bridge loan agreements with existing shareholders to ensure further liquidity is available to Kinarus during the period of time required for bridging the pending transfer of funds pursuant to a CHF1.5 million convertible loan investment from ChaoDian (Hangzhou) Investment Management Co (CDIM), in Kinarus.
  • The bridge loans are immediately available and Kinarus can decide when to request delivery of funds, , depending on the settlement of the funds to be transfer from CDIM.
  • Dr Hari Kumar, Chairman of the Board of Kinarus Therapeutics Holding AG, commented: “While CDIM’s commitment to Kinarus has not waivered, there are customary bureaucratic and regulatory processes that need to be respected when Chinese groups invest abroad.
  • Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.

Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting

Retrieved on: 
Friday, June 2, 2023
Exercise, Drug development, Probability, Therapy, Bank statement, Radisson Blu Hotel Hamburg, AGM, KNRS, CEST, Knowledge, Annual report, Pioglitazone, Proxy, Automobile License Plate Collectors Association, Annual general meeting, Audit, Muthiri kinaru

Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the invitation to the 2023 Annual General Meeting ("AGM"), which will be held at 10 a.m. CEST on Wednesday, June 28, 2023 at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.

Key Points: 
  • Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the invitation to the 2023 Annual General Meeting ("AGM"), which will be held at 10 a.m. CEST on Wednesday, June 28, 2023 at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.
  • For information on the agenda items and proposals of the board of directors as well as on how to attend the 2023 Annual General Meeting, exercise voting rights or issue voting instructions to the independent proxy, shareholders can access the invitation to the 2023 Annual General Meeting at https://ir.kinarus.com/2023-agm/ .
  • The 2023 Annual General Meeting will be conducted in English.
  • A record of the resolutions taken by the 2023 Annual General Meeting will be available after the 2023 Annual General Meeting on the Company’s website at https://ir.kinarus.com/2023-agm/ .

Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting

Retrieved on: 
Friday, June 2, 2023
Exercise, Drug development, Probability, Therapy, Bank statement, Radisson Blu Hotel Hamburg, AGM, KNRS, CEST, Knowledge, Annual report, Pioglitazone, Proxy, Automobile License Plate Collectors Association, Annual general meeting, Audit, Muthiri kinaru

Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the invitation to the 2023 Annual General Meeting ("AGM"), which will be held at 10 a.m. CEST on Wednesday, June 28, 2023 at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.

Key Points: 
  • Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the invitation to the 2023 Annual General Meeting ("AGM"), which will be held at 10 a.m. CEST on Wednesday, June 28, 2023 at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.
  • For information on the agenda items and proposals of the board of directors as well as on how to attend the 2023 Annual General Meeting, exercise voting rights or issue voting instructions to the independent proxy, shareholders can access the invitation to the 2023 Annual General Meeting at https://ir.kinarus.com/2023-agm/ .
  • The 2023 Annual General Meeting will be conducted in English.
  • A record of the resolutions taken by the 2023 Annual General Meeting will be available after the 2023 Annual General Meeting on the Company’s website at https://ir.kinarus.com/2023-agm/ .

Kinarus Therapeutics Group Reports 2022 Annual Results

Retrieved on: 
Wednesday, May 31, 2023
Insurance, Maintenance, Therapy, File, D&O, Hangzhou, AMD, Annual, COVID-19, Tax, Federal Office of Public Health, FOPH, Federal, IP, KNRS, Consultant, Reverse takeover, Public health, Companion dog, Patient, Annual report, Research, IPF, CHF, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Cryptocurrency, Muthiri kinaru

Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the Annual Report with full year audited consolidated financial results for the year ended 31 December 2022.

Key Points: 
  • Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today published the Annual Report with full year audited consolidated financial results for the year ended 31 December 2022.
  • The reporting of audited financial results follows the announcement of the unaudited key financial figures published on 5 May 2023.
  • On 28 April 2023, Kinarus announced that the SIX Exchange Regulation ("SER") approved a deadline extension until the end of May 2023 for the publication of the Kinarus’ 2022 annual report and asked Kinarus to report unaudited key financial figures for the year ended 31 December 2022.
  • To this end, Kinarus engaged Great Health Companion Group Ltd., to explore financing and partnering options for KIN001 in China.

Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management

Retrieved on: 
Thursday, May 11, 2023
MAP, Idiopathic disease, Partnership, Idiopathic pulmonary fibrosis, Drug development, Therapy, Probability, Hangzhou, AMD, KNRS, HIV disease progression rates, Patent, Patient, Disease, Knowledge, Mortality, API, IPF, Pioglitazone, CHF, Humanitarian use licenses, Pharmaceutical industry, Muthiri kinaru

Basel, Switzerland, May 10, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of a strategic convertible loan agreement for a CHF 1.5 million investment by ChaoDian (Hangzhou) Investment Management Co., Ltd., an investment company based in Hangzhou City, China (“CDIM”).

Key Points: 
  • Basel, Switzerland, May 10, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and ophthalmic diseases, today announced the signing of a strategic convertible loan agreement for a CHF 1.5 million investment by ChaoDian (Hangzhou) Investment Management Co., Ltd., an investment company based in Hangzhou City, China (“CDIM”).
  • Under the terms of the loan agreement, CDIM grants a subordinated loan in the amount of CHF 1.5 million to Kinarus for a fixed term of three years without any interest.
  • During the term of the agreement, the outstanding loan amount can be converted at any time into Kinarus shares with a nominal value of CHF 0.01 at a fixed conversion price of CHF 0.01 per Kinarus share.
  • Kinarus possesses the exclusive worldwide license to pamapimod, covering all indications, and has patented KIN001, its novel mechanism in combination with pioglitazone.